On Monday, February 26, the next meeting of the Transparency Council.
The agenda includes:
- Preparation of an opinion on the appropriateness of changing the reimbursement indication for the active substance carisprazine to: treatment of adult patients with schizophrenia with primary, predominant and persistent negative symptoms.
- Preparation of an opinion on the appropriateness of introducing a change in the existing content of the drug program B.101. "Treatment of patients with lipid disorders (ICD-10: E78.01, I21, I22, I25)".
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
